Literature DB >> 9279359

Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase.

H Handa1, U P Hegde, V M Kotelnikov, S D Mundle, L M Dong, P Burke, S Rose, F Gaskin, A Raza, H D Preisler.   

Abstract

Chronic myelogenous leukemia (CML) has a progressive course but little is known about the biologic characteristics of disease progression. This study was designed to assess the changes in cell proliferative characteristics, apoptosis, the expression of the bcl-2 and c-myc genes between the time of initial diagnosis and entrance into the blastic phase of the disease. We observed that the rate of cell proliferation decreased and the cell death rate did not significantly change as the disease accelerated. The level of bcl-2 expression was significantly higher in accelerated/blastic phase cells than in the chronic phase cells in the population as a whole, however, the bcl-2 expression level did not change in blast cell subpopulation. c-myc Expression was significantly higher in the blast cell subpopulation of accelerated/blastic phase than in that of earlier phases of the disease. In conclusion, the characteristics of CML cells, namely proliferation rate, c-myc and bcl-2 change during the course of the disease. It is possible that the change in c-myc expression plays a causative role in evolution of the blastic phase from the chronic phase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279359     DOI: 10.1016/s0145-2126(97)00006-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

Review 1.  Inhibition of Ras-mediated signaling pathways in CML stem cells.

Authors:  Jessika Bertacchini; Neda Ketabchi; Laura Mediani; Silvano Capitani; Sandra Marmiroli; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

2.  Myc roles in hematopoiesis and leukemia.

Authors:  M Dolores Delgado; Javier León
Journal:  Genes Cancer       Date:  2010-06

Review 3.  MYC oncogene in myeloid neoplasias.

Authors:  M Dolores Delgado; Marta Albajar; M Teresa Gomez-Casares; Ana Batlle; Javier León
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

4.  Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.

Authors:  Siddhartha Jaiswal; David Traver; Toshihiro Miyamoto; Koichi Akashi; Eric Lagasse; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-30       Impact factor: 11.205

5.  Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Scott A Tomlins; Vasudeva Mahavisno; Nicole Kasper; Radhika Varambally; Terrence R Barrette; Debashis Ghosh; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

Review 6.  Cellular and molecular themes in apoptosis.

Authors:  Faris Q Alenzi; Anthony N Warrens
Journal:  Wien Klin Wochenschr       Date:  2003-09-15       Impact factor: 1.704

7.  The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias.

Authors:  Flora Tzifi; Christina Economopoulou; Dimitrios Gourgiotis; Alexandros Ardavanis; Sotirios Papageorgiou; Andreas Scorilas
Journal:  Adv Hematol       Date:  2011-09-14

8.  BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Authors:  Nitesh Sharma; Vera Magistroni; Rocco Piazza; Stefania Citterio; Caterina Mezzatesta; Praveen Khandelwal; Alessandra Pirola; Carlo Gambacorti-Passerini
Journal:  Mol Cancer       Date:  2015-07-16       Impact factor: 27.401

9.  On the Power of Additional and Complex Chromosomal Aberrations in CML.

Authors:  Karin M Greulich-Bode; Barbara Heinze
Journal:  Curr Genomics       Date:  2012-09       Impact factor: 2.236

10.  Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth.

Authors:  Jonathan W Kotula; Jinpeng Sun; Margie Li; Elizabeth D Pratico; Mark P Fereshteh; Douglas P Ahrens; Bruce A Sullenger; Jeffrey J Kovacs
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.